
    
      Ginkgolides Meglumine Injection was jointly developed by China Pharmaceutical University and
      Jiangsu Kanion Pharmaceutical Co., Ltd. Its pharmacal ingredients are ginkgo lactones ,
      ginkgo lactone B, ginkgo lactone K, etc; Excipients for meglumine, citric acid, sodium
      chloride. It is used to treat stroke (mild-to-moderate cerebral infarction) in recovery
      phlegm and Syndrome of Intermingled Phlegm and Blood Stasis.

      The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the
      treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
    
  